Cargando…

Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study

INTRODUCTION: Approximately 15 to 33% of all dialysis treatments are complicated by intradialytic hypotension (IDH). In this study, we tested the hypothesis that the intravenous administration of hydrocortisone prior to HD treatment could prevent IDH or at least decrease the drop in the blood pressu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhawari, Hussein H., Alshelleh, Sameeha, Alhawari, Hussam H., Alawwa, Izzat Ahmad, AlRyalat, Saif Aldeen, Mesmar, Ahmad, Ojjoh, Khaled, Alzoubi, Karem H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654564/
https://www.ncbi.nlm.nih.gov/pubmed/34901264
http://dx.doi.org/10.1155/2020/4987547
_version_ 1784611888567418880
author Alhawari, Hussein H.
Alshelleh, Sameeha
Alhawari, Hussam H.
Alawwa, Izzat Ahmad
AlRyalat, Saif Aldeen
Mesmar, Ahmad
Ojjoh, Khaled
Alzoubi, Karem H.
author_facet Alhawari, Hussein H.
Alshelleh, Sameeha
Alhawari, Hussam H.
Alawwa, Izzat Ahmad
AlRyalat, Saif Aldeen
Mesmar, Ahmad
Ojjoh, Khaled
Alzoubi, Karem H.
author_sort Alhawari, Hussein H.
collection PubMed
description INTRODUCTION: Approximately 15 to 33% of all dialysis treatments are complicated by intradialytic hypotension (IDH). In this study, we tested the hypothesis that the intravenous administration of hydrocortisone prior to HD treatment could prevent IDH or at least decrease the drop in the blood pressure resulting from IDH. METHODS: This study was approved by our local ethics committee/IRB (2017/87) and by the Jordan Food and Drug Administration (7/clinical/18). Additionally, it is registered on ClinicalTrials.gov (NCT03465007). In this preliminary investigational study, we screened all chronic hemodialysis patients at our clinic who were 18 years of age or older (n = 82) for IDH. There were 14 patients included in the interventional part of this study; patients were given IV hydrocortisone for 3 consecutive HD sessions, followed or preceded by 3 intervention-free sessions where they were given 5 ml of saline as a placebo. RESULTS: The initial total sample size was 82 patients. The frequency of IDH at our clinic was 24.4%. Fourteen out of the 20 patients who were diagnosed with IDH agreed to enroll in the interventional part of our study. The mean age of the patients in the interventional part of our study was 53.5 years (±10.3). These patients included 5 (35.7%) men and 9 (64.3%) women. Upon comparing the number of hypotensive attacks with and without the hydrocortisone administration, we found a significant difference (p = 0.003) between the hydrocortisone and placebo treatments in which 12 (85.7%) patients had fewer IDH episodes with the hydrocortisone treatment than with placebo. CONCLUSION: This preliminary investigational study found that the administration of a stress dose of hydrocortisone prior to hemodialysis could be an effective measure for preventing or minimizing the risk of IDH episodes. Additional prospective studies on this subject are needed. Ruling out adrenal insufficiency in patients diagnosed with IDH is also crucial.
format Online
Article
Text
id pubmed-8654564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86545642021-12-09 Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study Alhawari, Hussein H. Alshelleh, Sameeha Alhawari, Hussam H. Alawwa, Izzat Ahmad AlRyalat, Saif Aldeen Mesmar, Ahmad Ojjoh, Khaled Alzoubi, Karem H. Biomed Res Int Clinical Study INTRODUCTION: Approximately 15 to 33% of all dialysis treatments are complicated by intradialytic hypotension (IDH). In this study, we tested the hypothesis that the intravenous administration of hydrocortisone prior to HD treatment could prevent IDH or at least decrease the drop in the blood pressure resulting from IDH. METHODS: This study was approved by our local ethics committee/IRB (2017/87) and by the Jordan Food and Drug Administration (7/clinical/18). Additionally, it is registered on ClinicalTrials.gov (NCT03465007). In this preliminary investigational study, we screened all chronic hemodialysis patients at our clinic who were 18 years of age or older (n = 82) for IDH. There were 14 patients included in the interventional part of this study; patients were given IV hydrocortisone for 3 consecutive HD sessions, followed or preceded by 3 intervention-free sessions where they were given 5 ml of saline as a placebo. RESULTS: The initial total sample size was 82 patients. The frequency of IDH at our clinic was 24.4%. Fourteen out of the 20 patients who were diagnosed with IDH agreed to enroll in the interventional part of our study. The mean age of the patients in the interventional part of our study was 53.5 years (±10.3). These patients included 5 (35.7%) men and 9 (64.3%) women. Upon comparing the number of hypotensive attacks with and without the hydrocortisone administration, we found a significant difference (p = 0.003) between the hydrocortisone and placebo treatments in which 12 (85.7%) patients had fewer IDH episodes with the hydrocortisone treatment than with placebo. CONCLUSION: This preliminary investigational study found that the administration of a stress dose of hydrocortisone prior to hemodialysis could be an effective measure for preventing or minimizing the risk of IDH episodes. Additional prospective studies on this subject are needed. Ruling out adrenal insufficiency in patients diagnosed with IDH is also crucial. Hindawi 2020-05-05 /pmc/articles/PMC8654564/ /pubmed/34901264 http://dx.doi.org/10.1155/2020/4987547 Text en Copyright © 2020 Hussein H. Alhawari et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Alhawari, Hussein H.
Alshelleh, Sameeha
Alhawari, Hussam H.
Alawwa, Izzat Ahmad
AlRyalat, Saif Aldeen
Mesmar, Ahmad
Ojjoh, Khaled
Alzoubi, Karem H.
Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title_full Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title_fullStr Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title_full_unstemmed Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title_short Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study
title_sort effect of hydrocortisone on intradialytic hypotension: a preliminary investigational study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654564/
https://www.ncbi.nlm.nih.gov/pubmed/34901264
http://dx.doi.org/10.1155/2020/4987547
work_keys_str_mv AT alhawarihusseinh effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT alshellehsameeha effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT alhawarihussamh effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT alawwaizzatahmad effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT alryalatsaifaldeen effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT mesmarahmad effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT ojjohkhaled effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy
AT alzoubikaremh effectofhydrocortisoneonintradialytichypotensionapreliminaryinvestigationalstudy